{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T04:24:32Z","timestamp":1780374272049,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T00:00:00Z","timestamp":1536019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T00:00:00Z","timestamp":1536019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Acitretin is widely used to treat psoriasis, but the efficacy varies significantly among individuals. To explore the association between polymorphisms and acitretin efficacy, we enrolled 46 and 105 Chinese Han psoriasis vulgaris patients for discovery and validation phases, respectively. The patients were treated with acitretin (30\u2009mg\/day) and calcipotriol ointment for at least 8 weeks, and their genotypes were detected. The wild-type genes and variants were transfected into HEK293 cells, which were then incubated\u00a0with acitretin. The cellular acitretin concentration was measured by liquid chromatography-mass spectrometry. We found that the polymorphisms rs4149056 in the <jats:italic>SLCO1B1<\/jats:italic> gene and rs2282143 in the <jats:italic>SLC22A1<\/jats:italic> gene were associated with efficacy, both in the discovery (<jats:italic>P<\/jats:italic>\u2009=\u20090.013 and <jats:italic>P<\/jats:italic>\u2009=\u20090.002) and validation phases (<jats:italic>P<\/jats:italic>\u2009=\u20090.028 and <jats:italic>P<\/jats:italic>\u2009=\u20090.014), based on a 50% reduction from before to after treatment of the psoriasis area severity index (PASI50). When the PASI75 was used as an efficacy cutoff, a similar conclusion was drawn. The uptake of acitretin was lower with the rs4149056C (<jats:italic>P<\/jats:italic>\u2009=\u20090.002) and rs2282143T alleles (<jats:italic>P<\/jats:italic>\u2009=\u20090.038) than\u00a0the wild-type alleles. Our results imply that the rs4149056C and rs2282143T variants decrease the acitretin uptake, and significantly associated with clinical effective responsiveness.<\/jats:p>","DOI":"10.1038\/s41598-018-31352-2","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T16:23:13Z","timestamp":1535559793000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Polymorphisms of SLCO1B1 rs4149056 and SLC22A1 rs2282143 are associated with responsiveness to acitretin in psoriasis patients"],"prefix":"10.1038","volume":"8","author":[{"given":"Wangqing","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,4]]},"reference":[{"key":"31352_CR1","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1038\/492S49a","volume":"492","author":"MP Grayson","year":"2012","unstructured":"Grayson, M. P. Nature 492, S49, https:\/\/doi.org\/10.1038\/492S49a (2012).","journal-title":"Nature"},{"key":"31352_CR2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2013005268","volume":"30","author":"AS Raut","year":"2013","unstructured":"Raut, A. S., Prabhu, R. H. & Patravale, V. B. Psoriasis clinical implications and treatment: a review. Critical reviews in therapeutic drug carrier systems 30, 183\u2013216 (2013).","journal-title":"Critical reviews in therapeutic drug carrier systems"},{"key":"31352_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/gigascience\/gix087","volume":"6","author":"C Zeng","year":"2017","unstructured":"Zeng, C. et al. Lipidomics profiling reveals the role of glycerophospholipid metabolism in psoriasis. Giga Science 6, 1\u201311, https:\/\/doi.org\/10.1093\/gigascience\/gix087 (2017).","journal-title":"Giga Science"},{"key":"31352_CR4","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2165\/00063030-200013050-00003","volume":"13","author":"A Arechalde","year":"2000","unstructured":"Arechalde, A. & Saurat, J. H. Management of psoriasis: the position of retinoid drugs. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy 13, 327\u2013333 (2000).","journal-title":"BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy"},{"key":"31352_CR5","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00403-008-0872-z","volume":"300","author":"M Zhang","year":"2008","unstructured":"Zhang, M. et al. Effects of acitretin on proliferative inhibition and RANTES production of HaCaT cells. Archives of dermatological research 300, 575\u2013581, https:\/\/doi.org\/10.1007\/s00403-008-0872-z (2008).","journal-title":"Archives of dermatological research"},{"key":"31352_CR6","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/ijd.12365","volume":"53","author":"S Dogra","year":"2014","unstructured":"Dogra, S. & Yadav, S. Acitretin in psoriasis: an evolving scenario. International journal of dermatology 53, 525\u2013538, https:\/\/doi.org\/10.1111\/ijd.12365 (2014).","journal-title":"International journal of dermatology"},{"key":"31352_CR7","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1111\/j.1346-8138.2012.01637.x","volume":"39","author":"X Niu","year":"2012","unstructured":"Niu, X. et al. Acitretin exerted a greater influence on T-helper (Th)1 and Th17 than on Th2 cells in treatment of psoriasis vulgaris. The Journal of dermatology 39, 916\u2013921, https:\/\/doi.org\/10.1111\/j.1346-8138.2012.01637.x (2012).","journal-title":"The Journal of dermatology"},{"key":"31352_CR8","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.ad.2013.01.003","volume":"104","author":"G Carretero","year":"2013","unstructured":"Carretero, G. et al. Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology. Actas dermo-sifiliograficas 104, 598\u2013616, https:\/\/doi.org\/10.1016\/j.adengl.2013.01.001 (2013).","journal-title":"Actas dermo-sifiliograficas"},{"key":"31352_CR9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.2340\/00015555-1921","volume":"95","author":"A Borghi","year":"2015","unstructured":"Borghi, A., Corazza, M., Bertoldi, A. M., Caroppo, F. & Virgili, A. Low-dose acitretin in treatment of plaque-type psoriasis: descriptive study of efficacy and safety. Acta dermato-venereologica 95, 332\u2013336, https:\/\/doi.org\/10.2340\/00015555-1921 (2015).","journal-title":"Acta dermato-venereologica"},{"key":"31352_CR10","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/archderm.142.8.1000","volume":"142","author":"DJ Pearce","year":"2006","unstructured":"Pearce, D. J. et al. Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis. Archives of dermatology 142, 1000\u20131004, https:\/\/doi.org\/10.1001\/archderm.142.8.1000 (2006).","journal-title":"Archives of dermatology"},{"key":"31352_CR11","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1111\/j.1365-2133.2010.09755.x","volume":"162","author":"AD Ormerod","year":"2010","unstructured":"Ormerod, A. D., Campalani, E. & Goodfield, M. J. British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology. The British journal of dermatology 162, 952\u2013963, https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09755.x (2010).","journal-title":"The British journal of dermatology"},{"key":"31352_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1124\/pr.110.002857","volume":"63","author":"M Niemi","year":"2011","unstructured":"Niemi, M., Pasanen, M. K. & Neuvonen, P. J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacological reviews 63, 157\u2013181, https:\/\/doi.org\/10.1124\/pr.110.002857 (2011).","journal-title":"Pharmacological reviews"},{"key":"31352_CR13","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nature15817","volume":"526","author":"MV Relling","year":"2015","unstructured":"Relling, M. V. & Evans, W. E. Pharmacogenomics in the clinic. Nature 526, 343\u2013350, https:\/\/doi.org\/10.1038\/nature15817 (2015).","journal-title":"Nature"},{"key":"31352_CR14","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1124\/dmd.106.012351","volume":"34","author":"C Chang","year":"2006","unstructured":"Chang, C., Bahadduri, P. M., Polli, J. E., Swaan, P. W. & Ekins, S. Rapid identification of P-glycoprotein substrates and inhibitors. Drug metabolism and disposition: the biological fate of chemicals 34, 1976\u20131984, https:\/\/doi.org\/10.1124\/dmd.106.012351 (2006).","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"},{"key":"31352_CR15","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000334300","volume":"10","author":"D Holthoewer","year":"2012","unstructured":"Holthoewer, D. et al. Acitretin, an enhancer of alpha-secretase expression, crosses the blood-brain barrier and is not eliminated by P-glycoprotein. Neuro-degenerative diseases 10, 224\u2013228, https:\/\/doi.org\/10.1159\/000334300 (2012).","journal-title":"Neuro-degenerative diseases"},{"key":"31352_CR16","doi-asserted-by":"publisher","unstructured":"Chen, W., Wu, L., Zhu, W. & Chen, X. The polymorphisms of growth factor genes (VEGFA & EGF) were associated with response to acitretin in psoriasis. Personalized medicine, https:\/\/doi.org\/10.2217\/pme-2017-0085 (2018).","DOI":"10.2217\/pme-2017-0085"},{"key":"31352_CR17","doi-asserted-by":"publisher","unstructured":"Zhou, X. et al. Correction: Xingchen Zhou, et al. Whole Exome Sequencing in Psoriasis Patients Contributes to Studies of Acitretin Treatment Difference. International journal of molecular sciences 18, https:\/\/doi.org\/10.3390\/ijms18091899 (2017).","DOI":"10.3390\/ijms18091899"},{"key":"31352_CR18","doi-asserted-by":"publisher","first-page":"e4637","DOI":"10.7717\/peerj.4637","volume":"6","author":"X Zhou","year":"2018","unstructured":"Zhou, X. et al. Frizzled-related proteins 4 (SFRP4) rs1802073G allele predicts the elevated serum lipid levels during acitretin treatment in psoriatic patients from Hunan, China. PeerJ 6, e4637, https:\/\/doi.org\/10.7717\/peerj.4637 (2018).","journal-title":"PeerJ"},{"key":"31352_CR19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.clpt.2006.01.011","volume":"79","author":"K Maeda","year":"2006","unstructured":"Maeda, K. et al. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clinical pharmacology and therapeutics 79, 427\u2013439, https:\/\/doi.org\/10.1016\/j.clpt.2006.01.011 (2006).","journal-title":"Clinical pharmacology and therapeutics"},{"key":"31352_CR20","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.clpt.2005.07.005","volume":"78","author":"LI Kajosaari","year":"2005","unstructured":"Kajosaari, L. I. et al. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clinical pharmacology and therapeutics 78, 388\u2013399, https:\/\/doi.org\/10.1016\/j.clpt.2005.07.005 (2005).","journal-title":"Clinical pharmacology and therapeutics"},{"key":"31352_CR21","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1182\/blood-2012-01-405035","volume":"121","author":"A Giannoudis","year":"2013","unstructured":"Giannoudis, A. et al. The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. Blood 121, 628\u2013637, https:\/\/doi.org\/10.1182\/blood-2012-01-405035 (2013).","journal-title":"Blood"},{"key":"31352_CR22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/bdd.1783","volume":"33","author":"MK Choi","year":"2012","unstructured":"Choi, M. K. & Song, I. S. Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake. Biopharmaceutics & drug disposition 33, 170\u2013178, https:\/\/doi.org\/10.1002\/bdd.1783 (2012).","journal-title":"Biopharmaceutics & drug disposition"},{"key":"31352_CR23","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.bbrc.2003.11.175","volume":"313","author":"T Sakata","year":"2004","unstructured":"Sakata, T. et al. Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochemical and biophysical research communications 313, 789\u2013793 (2004).","journal-title":"Biochemical and biophysical research communications"},{"key":"31352_CR24","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000083509","volume":"210","author":"J Schmitt","year":"2005","unstructured":"Schmitt, J. & Wozel, G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology (Basel, Switzerland) 210, 194\u2013199, https:\/\/doi.org\/10.1159\/000083509 (2005).","journal-title":"Dermatology (Basel, Switzerland)"},{"key":"31352_CR25","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.jaad.2003.09.014","volume":"50","author":"CS Carlin","year":"2004","unstructured":"Carlin, C. S., Feldman, S. R., Krueger, J. G., Menter, A. & Krueger, G. G. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. Journal of the American Academy of Dermatology 50, 859\u2013866, https:\/\/doi.org\/10.1016\/j.jaad.2003.09.014 (2004).","journal-title":"Journal of the American Academy of Dermatology"},{"key":"31352_CR26","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1111\/j.1365-2125.2011.04150.x","volume":"73","author":"L-X Wu","year":"2012","unstructured":"Wu, L.-X. et al. Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment. British journal of clinical pharmacology 73, 750\u2013757, https:\/\/doi.org\/10.1111\/j.1365-2125.2011.04150.x (2012).","journal-title":"British journal of clinical pharmacology"},{"key":"31352_CR27","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.3390\/molecules19011189","volume":"19","author":"JB Peng","year":"2014","unstructured":"Peng, J. B. et al. Validation of a liquid chromatography-electrospray ionization-tandem mass spectrometry method for determination of all-trans retinoic acid in human plasma and its application to a bioequivalence study. Molecules (Basel, Switzerland) 19, 1189\u20131200, https:\/\/doi.org\/10.3390\/molecules19011189 (2014).","journal-title":"Molecules (Basel, Switzerland)"},{"key":"31352_CR28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.taap.2013.08.024","volume":"273","author":"Q Li","year":"2013","unstructured":"Li, Q. et al. Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs). Toxicology and applied pharmacology 273, 100\u2013109, https:\/\/doi.org\/10.1016\/j.taap.2013.08.024 (2013).","journal-title":"Toxicology and applied pharmacology"},{"key":"31352_CR29","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2165\/00003088-199937040-00001","volume":"37","author":"DD Tang-Liu","year":"1999","unstructured":"Tang-Liu, D. D., Matsumoto, R. M. & Usansky, J. I. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clinical pharmacokinetics 37, 273\u2013287, https:\/\/doi.org\/10.2165\/00003088-199937040-00001 (1999).","journal-title":"Clinical pharmacokinetics"},{"key":"31352_CR30","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/sj.jid.5700096","volume":"126","author":"HS Young","year":"2006","unstructured":"Young, H. S. et al. Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. The Journal of investigative dermatology 126, 453\u2013459, https:\/\/doi.org\/10.1038\/sj.jid.5700096 (2006).","journal-title":"The Journal of investigative dermatology"},{"key":"31352_CR31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jdermsci.2015.06.014","volume":"79","author":"Y Zhao","year":"2015","unstructured":"Zhao, Y. et al. VDR gene polymorphisms are associated with the clinical response to calcipotriol in psoriatic patients. Journal of dermatological science 79, 305\u2013307, https:\/\/doi.org\/10.1016\/j.jdermsci.2015.06.014 (2015).","journal-title":"Journal of dermatological science"},{"key":"31352_CR32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/tpj.2010.92","volume":"12","author":"LR Brunham","year":"2012","unstructured":"Brunham, L. R. et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. The pharmacogenomics journal 12, 233\u2013237, https:\/\/doi.org\/10.1038\/tpj.2010.92 (2012).","journal-title":"The pharmacogenomics journal"},{"key":"31352_CR33","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/clpt.2013.161","volume":"94","author":"DF Carr","year":"2013","unstructured":"Carr, D. F. et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clinical pharmacology and therapeutics 94, 695\u2013701, https:\/\/doi.org\/10.1038\/clpt.2013.161 (2013).","journal-title":"Clinical pharmacology and therapeutics"},{"key":"31352_CR34","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1093\/eurheartj\/ehs344","volume":"34","author":"JC Hopewell","year":"2013","unstructured":"Hopewell, J. C. et al. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study. European heart journal 34, 982\u2013992, https:\/\/doi.org\/10.1093\/eurheartj\/ehs344 (2013).","journal-title":"European heart journal"},{"key":"31352_CR35","doi-asserted-by":"publisher","first-page":"7902","DOI":"10.1128\/MCB.23.21.7902-7908.2003","volume":"23","author":"JW Jonker","year":"2003","unstructured":"Jonker, J. W., Wagenaar, E., Van Eijl, S. & Schinkel, A. H. Deficiency in the organic cation transporters 1 and 2 (Oct1\/Oct2 [Slc22a1\/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol 23, 7902\u20137908 (2003).","journal-title":"Mol Cell Biol"},{"key":"31352_CR36","doi-asserted-by":"publisher","first-page":"5902","DOI":"10.1073\/pnas.0730858100","volume":"100","author":"Y Shu","year":"2003","unstructured":"Shu, Y. et al. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proceedings of the National Academy of Sciences of the United States of America 100, 5902\u20135907, https:\/\/doi.org\/10.1073\/pnas.0730858100 (2003).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"31352_CR37","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s00535-013-0795-0","volume":"49","author":"Y Ohishi","year":"2014","unstructured":"Ohishi, Y. et al. Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patients. Journal of gastroenterology 49, 332\u2013342, https:\/\/doi.org\/10.1007\/s00535-013-0795-0 (2014).","journal-title":"Journal of gastroenterology"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31352-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31352-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31352-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T09:08:41Z","timestamp":1671613721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-31352-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,4]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["31352"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-31352-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,4]]},"assertion":[{"value":"1 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"13182"}}